|
gptkbp:instance_of
|
gptkb:Antihero
|
|
gptkbp:administered_by
|
oral tablet
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
1938
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Dilantin
gptkb:Phenytek
Dilantin-125
|
|
gptkbp:casnumber
|
57-41-0
|
|
gptkbp:chemical_formula
|
C15 H12 N2 O2
|
|
gptkbp:contraindication
|
pregnancy
hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Parke-Davis
1930s
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenytoin
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:warfarin
oral contraceptives
|
|
gptkbp:lifespan
|
7 to 42 hours
|
|
gptkbp:mechanism_of_action
|
sodium channel blocker
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
non-linear kinetics
|
|
gptkbp:related_to
|
gptkb:gabapentin
gptkb:cannabidiol
gptkb:phenobarbital
gptkb:brivaracetam
gptkb:lamotrigine
gptkb:valproate
gptkb:carbamazepine
levetiracetam
pregabalin
oxcarbazepine
clobazam
eslicarbazepine acetate
fosphenytoin
lacosamide
perampanel
rufinamide
stiripentol
sultiame
topiramate
zonisamide
|
|
gptkbp:side_effect
|
dizziness
nausea
ataxia
gingival hyperplasia
|
|
gptkbp:treatment
|
gptkb:epilepsy
status epilepticus
|
|
gptkbp:used_for
|
seizure control
|
|
gptkbp:bfsParent
|
gptkb:Equetro
|
|
gptkbp:bfsLayer
|
6
|